Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 113

1.

Anti-idiotypic antibodies elicit anti-HIV-1-specific B cell responses.

Dosenovic P, Pettersson AK, Wall A, Thientosapol ES, Feng J, Weidle C, Bhullar K, Kara EE, Hartweger H, Pai JA, Gray MD, Parks KR, Taylor JJ, Pancera M, Stamatatos L, Nussenzweig MC, McGuire AT.

J Exp Med. 2019 Oct 7;216(10):2316-2330. doi: 10.1084/jem.20190446. Epub 2019 Jul 25.

2.

Detection and activation of HIV broadly neutralizing antibody precursor B cells using anti-idiotypes.

Bancroft T, DeBuysscher BL, Weidle C, Schwartz A, Wall A, Gray MD, Feng J, Steach HR, Fitzpatrick KS, Gewe MM, Skog PD, Doyle-Cooper C, Ota T, Strong RK, Nemazee D, Pancera M, Stamatatos L, McGuire AT, Taylor JJ.

J Exp Med. 2019 Oct 7;216(10):2331-2347. doi: 10.1084/jem.20190164. Epub 2019 Jul 25.

PMID:
31345930
3.

Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques.

Escolano A, Gristick HB, Abernathy ME, Merkenschlager J, Gautam R, Oliveira TY, Pai J, West AP Jr, Barnes CO, Cohen AA, Wang H, Golijanin J, Yost D, Keeffe JR, Wang Z, Zhao P, Yao KH, Bauer J, Nogueira L, Gao H, Voll AV, Montefiori DC, Seaman MS, Gazumyan A, Silva M, McGuire AT, Stamatatos L, Irvine DJ, Wells L, Martin MA, Bjorkman PJ, Nussenzweig MC.

Nature. 2019 Jun;570(7762):468-473. doi: 10.1038/s41586-019-1250-z. Epub 2019 May 29.

PMID:
31142836
4.

HIV-specific humoral immune responses by CRISPR/Cas9-edited B cells.

Hartweger H, McGuire AT, Horning M, Taylor JJ, Dosenovic P, Yost D, Gazumyan A, Seaman MS, Stamatatos L, Jankovic M, Nussenzweig MC.

J Exp Med. 2019 Jun 3;216(6):1301-1310. doi: 10.1084/jem.20190287. Epub 2019 Apr 11.

PMID:
30975893
5.

Correction: HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies.

LaBranche CC, McGuire AT, Gray MD, Behrens S, Chen X, Zhou T, Sattentau QJ, Peacock J, Eaton A, Greene K, Gao H, Tang H, Perez LG, Saunders KO, Kwong PD, Mascola JR, Haynes BF, Stamatatos L, Montefiori DC.

PLoS Pathog. 2019 Mar 26;15(3):e1007646. doi: 10.1371/journal.ppat.1007646. eCollection 2019 Mar.

6.

Inference of the HIV-1 VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier.

Bonsignori M, Scott E, Wiehe K, Easterhoff D, Alam SM, Hwang KK, Cooper M, Xia SM, Zhang R, Montefiori DC, Henderson R, Nie X, Kelsoe G, Moody MA, Chen X, Joyce MG, Kwong PD, Connors M, Mascola JR, McGuire AT, Stamatatos L, Medina-Ramírez M, Sanders RW, Saunders KO, Kepler TB, Haynes BF.

Immunity. 2018 Dec 18;49(6):1162-1174.e8. doi: 10.1016/j.immuni.2018.10.015. Epub 2018 Dec 11.

7.

Germline VRC01 antibody recognition of a modified clade C HIV-1 envelope trimer and a glycosylated HIV-1 gp120 core.

Borst AJ, Weidle CE, Gray MD, Frenz B, Snijder J, Joyce MG, Georgiev IS, Stewart-Jones GB, Kwong PD, McGuire AT, DiMaio F, Stamatatos L, Pancera M, Veesler D.

Elife. 2018 Nov 7;7. pii: e37688. doi: 10.7554/eLife.37688.

8.

HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies.

LaBranche CC, McGuire AT, Gray MD, Behrens S, Kwong PDK, Chen X, Zhou T, Sattentau QJ, Peacock J, Eaton A, Greene K, Gao H, Tang H, Perez LG, Chen X, Saunders KO, Kwong PD, Mascola JR, Haynes BF, Stamatatos L, Montefiori DC.

PLoS Pathog. 2018 Nov 5;14(11):e1007431. doi: 10.1371/journal.ppat.1007431. eCollection 2018 Nov. Erratum in: PLoS Pathog. 2019 Mar 26;15(3):e1007646.

9.

Live rubella vectors can express native HIV envelope glycoproteins targeted by broadly neutralizing antibodies and prime the immune response to an envelope protein boost.

Virnik K, Nesti E, Dail C, Scanlan A, Medvedev A, Vassell R, McGuire AT, Stamatatos L, Berkower I.

Vaccine. 2018 Aug 16;36(34):5166-5172. doi: 10.1016/j.vaccine.2018.07.010. Epub 2018 Jul 20.

PMID:
30037665
10.

B cell clonal lineage alterations upon recombinant HIV-1 envelope immunization of rhesus macaques.

Yacoob C, Lange MD, Cohen K, Lathia K, Feng J, Glenn J, Carbonetti S, Oliver B, Vigdorovich V, Sather DN, Stamatatos L.

PLoS Pathog. 2018 Jun 22;14(6):e1007120. doi: 10.1371/journal.ppat.1007120. eCollection 2018 Jun.

11.

Anti-HIV-1 B cell responses are dependent on B cell precursor frequency and antigen-binding affinity.

Dosenovic P, Kara EE, Pettersson AK, McGuire AT, Gray M, Hartweger H, Thientosapol ES, Stamatatos L, Nussenzweig MC.

Proc Natl Acad Sci U S A. 2018 May 1;115(18):4743-4748. doi: 10.1073/pnas.1803457115. Epub 2018 Apr 16.

12.

Structural Determination of the Broadly Reactive Anti-IGHV1-69 Anti-idiotypic Antibody G6 and Its Idiotope.

Avnir Y, Prachanronarong KL, Zhang Z, Hou S, Peterson EC, Sui J, Zayed H, Kurella VB, McGuire AT, Stamatatos L, Hilbert BJ, Bohn MF, Kowalik TF, Jensen JD, Finberg RW, Wang JP, Goodall M, Jefferis R, Zhu Q, Kurt Yilmaz N, Schiffer CA, Marasco WA.

Cell Rep. 2017 Dec 12;21(11):3243-3255. doi: 10.1016/j.celrep.2017.11.056.

13.

Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo.

Medina-Ramírez M, Garces F, Escolano A, Skog P, de Taeye SW, Del Moral-Sanchez I, McGuire AT, Yasmeen A, Behrens AJ, Ozorowski G, van den Kerkhof TLGM, Freund NT, Dosenovic P, Hua Y, Gitlin AD, Cupo A, van der Woude P, Golabek M, Sliepen K, Blane T, Kootstra N, van Breemen MJ, Pritchard LK, Stanfield RL, Crispin M, Ward AB, Stamatatos L, Klasse PJ, Moore JP, Nemazee D, Nussenzweig MC, Wilson IA, Sanders RW.

J Exp Med. 2017 Sep 4;214(9):2573-2590. doi: 10.1084/jem.20161160. Epub 2017 Aug 28.

14.

Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation.

Zhou T, Doria-Rose NA, Cheng C, Stewart-Jones GBE, Chuang GY, Chambers M, Druz A, Geng H, McKee K, Kwon YD, O'Dell S, Sastry M, Schmidt SD, Xu K, Chen L, Chen RE, Louder MK, Pancera M, Wanninger TG, Zhang B, Zheng A, Farney SK, Foulds KE, Georgiev IS, Joyce MG, Lemmin T, Narpala S, Rawi R, Soto C, Todd JP, Shen CH, Tsybovsky Y, Yang Y, Zhao P, Haynes BF, Stamatatos L, Tiemeyer M, Wells L, Scorpio DG, Shapiro L, McDermott AB, Mascola JR, Kwong PD.

Cell Rep. 2017 Apr 25;19(4):719-732. doi: 10.1016/j.celrep.2017.04.013.

15.

Germline-targeting immunogens.

Stamatatos L, Pancera M, McGuire AT.

Immunol Rev. 2017 Jan;275(1):203-216. doi: 10.1111/imr.12483. Review.

16.

Differences in Allelic Frequency and CDRH3 Region Limit the Engagement of HIV Env Immunogens by Putative VRC01 Neutralizing Antibody Precursors.

Yacoob C, Pancera M, Vigdorovich V, Oliver BG, Glenn JA, Feng J, Sather DN, McGuire AT, Stamatatos L.

Cell Rep. 2016 Nov 1;17(6):1560-1570. doi: 10.1016/j.celrep.2016.10.017.

17.

Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires.

Tian M, Cheng C, Chen X, Duan H, Cheng HL, Dao M, Sheng Z, Kimble M, Wang L, Lin S, Schmidt SD, Du Z, Joyce MG, Chen Y, DeKosky BJ, Chen Y, Normandin E, Cantor E, Chen RE, Doria-Rose NA, Zhang Y, Shi W, Kong WP, Choe M, Henry AR, Laboune F, Georgiev IS, Huang PY, Jain S, McGuire AT, Georgeson E, Menis S, Douek DC, Schief WR, Stamatatos L, Kwong PD, Shapiro L, Haynes BF, Mascola JR, Alt FW.

Cell. 2016 Sep 8;166(6):1471-1484.e18. doi: 10.1016/j.cell.2016.07.029.

18.

Repertoire comparison of the B-cell receptor-encoding loci in humans and rhesus macaques by next-generation sequencing.

Vigdorovich V, Oliver BG, Carbonetti S, Dambrauskas N, Lange MD, Yacoob C, Leahy W, Callahan J, Stamatatos L, Sather DN.

Clin Transl Immunology. 2016 Jul 22;5(7):e93. doi: 10.1038/cti.2016.42. eCollection 2016 Jul.

19.

Structural basis for germline antibody recognition of HIV-1 immunogens.

Scharf L, West AP, Sievers SA, Chen C, Jiang S, Gao H, Gray MD, McGuire AT, Scheid JF, Nussenzweig MC, Stamatatos L, Bjorkman PJ.

Elife. 2016 Mar 21;5. pii: e13783. doi: 10.7554/eLife.13783.

20.

Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens.

Hessell AJ, Malherbe DC, Pissani F, McBurney S, Krebs SJ, Gomes M, Pandey S, Sutton WF, Burwitz BJ, Gray M, Robins H, Park BS, Sacha JB, LaBranche CC, Fuller DH, Montefiori DC, Stamatatos L, Sather DN, Haigwood NL.

J Immunol. 2016 Apr 1;196(7):3064-78. doi: 10.4049/jimmunol.1500527. Epub 2016 Mar 4.

21.

Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice.

McGuire AT, Gray MD, Dosenovic P, Gitlin AD, Freund NT, Petersen J, Correnti C, Johnsen W, Kegel R, Stuart AB, Glenn J, Seaman MS, Schief WR, Strong RK, Nussenzweig MC, Stamatatos L.

Nat Commun. 2016 Feb 24;7:10618. doi: 10.1038/ncomms10618.

22.

Common Characteristics of HIV-Neutralizing Antibodies with a Fondness for Sugars.

McGuire AT, Stamatatos L.

Immunity. 2015 Nov 17;43(5):837-40. doi: 10.1016/j.immuni.2015.10.026.

23.

Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice.

Dosenovic P, von Boehmer L, Escolano A, Jardine J, Freund NT, Gitlin AD, McGuire AT, Kulp DW, Oliveira T, Scharf L, Pietzsch J, Gray MD, Cupo A, van Gils MJ, Yao KH, Liu C, Gazumyan A, Seaman MS, Björkman PJ, Sanders RW, Moore JP, Stamatatos L, Schief WR, Nussenzweig MC.

Cell. 2015 Jun 18;161(7):1505-15. doi: 10.1016/j.cell.2015.06.003.

24.

Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors.

Zhou T, Lynch RM, Chen L, Acharya P, Wu X, Doria-Rose NA, Joyce MG, Lingwood D, Soto C, Bailer RT, Ernandes MJ, Kong R, Longo NS, Louder MK, McKee K, O'Dell S, Schmidt SD, Tran L, Yang Z, Druz A, Luongo TS, Moquin S, Srivatsan S, Yang Y, Zhang B, Zheng A, Pancera M, Kirys T, Georgiev IS, Gindin T, Peng HP, Yang AS; NISC Comparative Sequencing Program, Mullikin JC, Gray MD, Stamatatos L, Burton DR, Koff WC, Cohen MS, Haynes BF, Casazza JP, Connors M, Corti D, Lanzavecchia A, Sattentau QJ, Weiss RA, West AP Jr, Bjorkman PJ, Scheid JF, Nussenzweig MC, Shapiro L, Mascola JR, Kwong PD.

Cell. 2015 Jun 4;161(6):1280-92. doi: 10.1016/j.cell.2015.05.007. Epub 2015 May 21.

25.
26.

HIV-1 single-stranded RNA induces CXCL13 secretion in human monocytes via TLR7 activation and plasmacytoid dendritic cell-derived type I IFN.

Cohen KW, Dugast AS, Alter G, McElrath MJ, Stamatatos L.

J Immunol. 2015 Mar 15;194(6):2769-75. doi: 10.4049/jimmunol.1400952. Epub 2015 Feb 9.

27.

A multivalent clade C HIV-1 Env trimer cocktail elicits a higher magnitude of neutralizing antibodies than any individual component.

Bricault CA, Kovacs JM, Nkolola JP, Yusim K, Giorgi EE, Shields JL, Perry J, Lavine CL, Cheung A, Ellingson-Strouss K, Rademeyer C, Gray GE, Williamson C, Stamatatos L, Seaman MS, Korber BT, Chen B, Barouch DH.

J Virol. 2015 Mar;89(5):2507-19. doi: 10.1128/JVI.03331-14. Epub 2014 Dec 24.

28.

HIV antibodies. Antigen modification regulates competition of broad and narrow neutralizing HIV antibodies.

McGuire AT, Dreyer AM, Carbonetti S, Lippy A, Glenn J, Scheid JF, Mouquet H, Stamatatos L.

Science. 2014 Dec 12;346(6215):1380-1383. doi: 10.1126/science.1259206.

29.

Generation and evaluation of clade C simian-human immunodeficiency virus challenge stocks.

Chang HW, Tartaglia LJ, Whitney JB, Lim SY, Sanisetty S, Lavine CL, Seaman MS, Rademeyer C, Williamson C, Ellingson-Strouss K, Stamatatos L, Kublin J, Barouch DH.

J Virol. 2015 Feb;89(4):1965-74. doi: 10.1128/JVI.03279-14. Epub 2014 Dec 3.

30.

Ontogeny of recognition specificity and functionality for the broadly neutralizing anti-HIV antibody 4E10.

Finton KA, Friend D, Jaffe J, Gewe M, Holmes MA, Larman HB, Stuart A, Larimore K, Greenberg PD, Elledge SJ, Stamatatos L, Strong RK.

PLoS Pathog. 2014 Sep 25;10(9):e1004403. doi: 10.1371/journal.ppat.1004403. eCollection 2014 Sep.

31.

Early preservation of CXCR5+ PD-1+ helper T cells and B cell activation predict the breadth of neutralizing antibody responses in chronic HIV-1 infection.

Cohen K, Altfeld M, Alter G, Stamatatos L.

J Virol. 2014 Nov;88(22):13310-21. doi: 10.1128/JVI.02186-14. Epub 2014 Sep 10.

32.

Emergence of broadly neutralizing antibodies and viral coevolution in two subjects during the early stages of infection with human immunodeficiency virus type 1.

Sather DN, Carbonetti S, Malherbe DC, Pissani F, Stuart AB, Hessell AJ, Gray MD, Mikell I, Kalams SA, Haigwood NL, Stamatatos L.

J Virol. 2014 Nov;88(22):12968-81. doi: 10.1128/JVI.01816-14. Epub 2014 Aug 13.

33.

Independent evolution of Fc- and Fab-mediated HIV-1-specific antiviral antibody activity following acute infection.

Dugast AS, Stamatatos L, Tonelli A, Suscovich TJ, Licht AF, Mikell I, Ackerman ME, Streeck H, Klasse PJ, Moore JP, Alter G.

Eur J Immunol. 2014 Oct;44(10):2925-37. doi: 10.1002/eji.201344305. Epub 2014 Aug 11.

34.

Molecular signatures of hemagglutinin stem-directed heterosubtypic human neutralizing antibodies against influenza A viruses.

Avnir Y, Tallarico AS, Zhu Q, Bennett AS, Connelly G, Sheehan J, Sui J, Fahmy A, Huang CY, Cadwell G, Bankston LA, McGuire AT, Stamatatos L, Wagner G, Liddington RC, Marasco WA.

PLoS Pathog. 2014 May 1;10(5):e1004103. doi: 10.1371/journal.ppat.1004103. eCollection 2014 May.

35.

Soluble HIV-1 envelope immunogens derived from an elite neutralizer elicit cross-reactive V1V2 antibodies and low potency neutralizing antibodies.

Carbonetti S, Oliver BG, Glenn J, Stamatatos L, Sather DN.

PLoS One. 2014 Jan 23;9(1):e86905. doi: 10.1371/journal.pone.0086905. eCollection 2014.

36.

Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D.

McGuire AT, Glenn JA, Lippy A, Stamatatos L.

J Virol. 2014 Mar;88(5):2645-57. doi: 10.1128/JVI.03228-13. Epub 2013 Dec 18. Erratum in: J Virol. 2015 May;89(9):5194.

37.

Restricting HIV-1 pathways for escape using rationally designed anti-HIV-1 antibodies.

Diskin R, Klein F, Horwitz JA, Halper-Stromberg A, Sather DN, Marcovecchio PM, Lee T, West AP Jr, Gao H, Seaman MS, Stamatatos L, Nussenzweig MC, Bjorkman PJ.

J Exp Med. 2013 Jun 3;210(6):1235-49. doi: 10.1084/jem.20130221. Epub 2013 May 27.

38.

Rational HIV immunogen design to target specific germline B cell receptors.

Jardine J, Julien JP, Menis S, Ota T, Kalyuzhniy O, McGuire A, Sok D, Huang PS, MacPherson S, Jones M, Nieusma T, Mathison J, Baker D, Ward AB, Burton DR, Stamatatos L, Nemazee D, Wilson IA, Schief WR.

Science. 2013 May 10;340(6133):711-6. doi: 10.1126/science.1234150. Epub 2013 Mar 28.

39.

Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies.

McGuire AT, Hoot S, Dreyer AM, Lippy A, Stuart A, Cohen KW, Jardine J, Menis S, Scheid JF, West AP, Schief WR, Stamatatos L.

J Exp Med. 2013 Apr 8;210(4):655-63. doi: 10.1084/jem.20122824. Epub 2013 Mar 25.

40.

Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs.

Hoot S, McGuire AT, Cohen KW, Strong RK, Hangartner L, Klein F, Diskin R, Scheid JF, Sather DN, Burton DR, Stamatatos L.

PLoS Pathog. 2013 Jan;9(1):e1003106. doi: 10.1371/journal.ppat.1003106. Epub 2013 Jan 3. Erratum in: PLoS Pathog. 2013 Jul;9(9). doi:10.1371/annotation/ed7c0148-97eb-4416-824d-6e6d1aaeceef.

41.

Evolution of cross-neutralizing antibody specificities to the CD4-BS and the carbohydrate cloak of the HIV Env in an HIV-1-infected subject.

Mikell I, Stamatatos L.

PLoS One. 2012;7(11):e49610. doi: 10.1371/journal.pone.0049610. Epub 2012 Nov 13.

42.

Broadly neutralizing antibodies developed by an HIV-positive elite neutralizer exact a replication fitness cost on the contemporaneous virus.

Sather DN, Carbonetti S, Kehayia J, Kraft Z, Mikell I, Scheid JF, Klein F, Stamatatos L.

J Virol. 2012 Dec;86(23):12676-85. doi: 10.1128/JVI.01893-12. Epub 2012 Sep 12.

43.

Silibinin inhibits HIV-1 infection by reducing cellular activation and proliferation.

McClure J, Lovelace ES, Elahi S, Maurice NJ, Wagoner J, Dragavon J, Mittler JE, Kraft Z, Stamatatos L, Horton H, De Rosa SC, Coombs RW, Polyak SJ.

PLoS One. 2012;7(7):e41832. doi: 10.1371/journal.pone.0041832. Epub 2012 Jul 25. Erratum in: PLoS One. 2012;7(10). doi: 10.1371/annotation/78ba072a-6b7a-430a-8fcd-ef020e4fc458. Stamatatos, Leonidis [corrected to Stamatatos, Leonidas].

44.

Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein.

Klein F, Gaebler C, Mouquet H, Sather DN, Lehmann C, Scheid JF, Kraft Z, Liu Y, Pietzsch J, Hurley A, Poignard P, Feizi T, Morris L, Walker BD, Fätkenheuer G, Seaman MS, Stamatatos L, Nussenzweig MC.

J Exp Med. 2012 Jul 30;209(8):1469-79. doi: 10.1084/jem.20120423. Epub 2012 Jul 23.

45.

Motif-optimized subtype A HIV envelope-based DNA vaccines rapidly elicit neutralizing antibodies when delivered sequentially.

Pissani F, Malherbe DC, Robins H, DeFilippis VR, Park B, Sellhorn G, Stamatatos L, Overbaugh J, Haigwood NL.

Vaccine. 2012 Aug 10;30(37):5519-26. doi: 10.1016/j.vaccine.2012.06.042. Epub 2012 Jun 27.

46.

HIV vaccine design: the neutralizing antibody conundrum.

Stamatatos L.

Curr Opin Immunol. 2012 Jun;24(3):316-23. doi: 10.1016/j.coi.2012.04.006. Epub 2012 May 15. Review. No abstract available.

PMID:
22595693
47.

Engineering, expression, purification, and characterization of stable clade A/B recombinant soluble heterotrimeric gp140 proteins.

Sellhorn G, Kraft Z, Caldwell Z, Ellingson K, Mineart C, Seaman MS, Montefiori DC, Lagerquist E, Stamatatos L.

J Virol. 2012 Jan;86(1):128-42. doi: 10.1128/JVI.06363-11. Epub 2011 Oct 26.

48.

HIV-1 gp120 induces expression of IL-6 through a nuclear factor-kappa B-dependent mechanism: suppression by gp120 specific small interfering RNA.

Shah A, Verma AS, Patel KH, Noel R, Rivera-Amill V, Silverstein PS, Chaudhary S, Bhat HK, Stamatatos L, Singh DP, Buch S, Kumar A.

PLoS One. 2011;6(6):e21261. doi: 10.1371/journal.pone.0021261. Epub 2011 Jun 21.

49.

Binding interactions between soluble HIV envelope glycoproteins and quaternary-structure-specific monoclonal antibodies PG9 and PG16.

Davenport TM, Friend D, Ellingson K, Xu H, Caldwell Z, Sellhorn G, Kraft Z, Strong RK, Stamatatos L.

J Virol. 2011 Jul;85(14):7095-107. doi: 10.1128/JVI.00411-11. Epub 2011 May 4.

50.

Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodies.

Malherbe DC, Doria-Rose NA, Misher L, Beckett T, Puryear WB, Schuman JT, Kraft Z, O'Malley J, Mori M, Srivastava I, Barnett S, Stamatatos L, Haigwood NL.

J Virol. 2011 Jun;85(11):5262-74. doi: 10.1128/JVI.02419-10. Epub 2011 Mar 23.

Supplemental Content

Loading ...
Support Center